ReviewMolecular diagnosis & therapy2026
TROP2-Targeted Therapeutics in Development to Treat Gastrointestinal Tumors.
Review in Molecular diagnosis & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Overexpression of trophoblast cell surface antigen 2 (TROP2) has been identified in various malignancies. Antibody-drug conjugates (ADCs) targeting TROP2 with topoisomerase 1 inhibitor chemotherapy payloads are currently marketed in breast and lung cancer. TROP2 ADCs currently in use carry unique toxicities and come with specifics in supportive care therapy. TROP2 investigation is highly prevalent in current oncology, with multiple TROP2-targeting agents in the investigative pipeline for a vast array of malignancies. Combination strategies are also being explored. Gastrointestinal (GI) malignancies represent a heterogeneous group of cancers-with some of the most common malignancies and some with a high incidence of cancer-related deaths-in dire need of newer therapies. Early phase 1/2 data show a spark of activity in reports on colorectal cancer and gastroesophageal cancer. Studies are underway for targeting TROP2 in colorectal cancer, pancreatic cancer, biliary tract cancers, and gastroesophageal cancers. Discovering more targeted therapy in GI malignancies is of utmost importance. This review will focus on the current progress of TROP2-targeting therapies in GI investigations, and what lies ahead for the future.
Indexed as
Identifiers
41670877What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.